

ЎЗБЕКИСТОН РЕСПУБЛИКАСИ СОҒЛИҚНИ САҚЛАШ ВАЗИРЛИГИ
ТОШКЕНТ ТИББИЁТ АКАДЕМИЯСИ

№9(1), 2025

2011 йилдан чиқа бошлаган

TOSHKENT TIBBIYOT AKADEMIYASI
AXBOROTNOMASI



ВЕСТНИК

ТАШКЕНТСКОЙ МЕДИЦИНСКОЙ АКАДЕМИИ

Тошкент



Выпуск набран и сверстан на компьютерном издательском комплексе

редакционно-издательского отдела Ташкентской медицинской академии

Начальник отдела: М. Н. Аслонов

Редактор русского текста: О.А. Козлова

Редактор узбекского текста: М.Г. Файзиева

Редактор английского текста: А.Х. Жураев

Компьютерная корректура: З.Т. Алюшева

Учредитель: Ташкентская медицинская академия

Издание зарегистрировано в Ташкентском Городском управлении печати и информации

Регистрационное свидетельство 02-00128

Журнал внесен в список, утвержденный приказом № 201/3 от 30 декабря 2013года

реестром ВАК в раздел медицинских наук

Рукописи, оформленные в соответствии с прилагаемыми правилами, просим направлять по адресу: 100109, Ташкент, ул. Фароби, 2,

Главный учебный корпус ТМА,

4-й этаж, комната 444.

Контактный телефон: 214 90 64

e-mail: rio-tma@mail.ru

rio@tma.uz

Формат 60x84 1/8. Усл. печ. л. 9,75.

Гарнитура «Cambria».

Тираж 150.

Цена договорная.

Отпечатано на ризографе редакционно-издательского отдела ТМА.

100109, Ташкент, ул. Фароби, 2.

Вестник ТМА №9(1), 2025

РЕДАКЦИОННАЯ КОЛЛЕГИЯ

Главный редактор

проф. А.К. Шадманов

Заместитель главного редактора

проф. О.Р.Тешаев

Ответственный секретарь

проф. Ф.Х.Иноятова

ЧЛЕНЫ РЕДАКЦИОННОЙ КОЛЛЕГИИ

акад. Аляви А.Л.

проф. Билалов Э.Н.

проф. Гадаев А.Г.

проф. Жае Вук Чои (Корея)

акад. Каримов Ш.И.

проф. Силина Т. (Украина)

акад. Курбанов Р.Д.

проф. Зуева Л. (Россия)

проф. Метин Онерчи (Турция)

проф. Ми Юн (Корея)

акад. Назыров Ф.Г.

проф. Нажмутдинова Д.К.

доц. Рахматуллин А.Р. (Россия)

проф. Саломова Ф.И.

проф. Трескач С. (Германия)

проф. Шайхова Г.И.

ЧЛЕНЫ РЕДАКЦИОННОГО СОВЕТА

Дмн. Абдуллаева Р.М.

проф. Акилов Ф.О. (Ташкент)

проф. Аллаева М.Д. (Ташкент)

проф. Хамдамов Б.З. (Бухара)

проф. Ирискулов Б.У. (Ташкент)

проф. Каримов М.Ш. (Ташкент)

проф. Маматкулов Б.М. (Ташкент)

проф. Охунов А.О. (Ташкент)

проф. Парпиева Н.Н. (Ташкент)

проф. Рахимбаева Г.С. (Ташкент)

проф. Хамраев А.А. (Ташкент)

проф. Холматова Б.Т. (Ташкент)

проф. Шагазатова Б.Х. (Ташкент)

EDITORIAL BOARD

Editor in chief

prof. A.K. Shadmanov

Deputy Chief Editor

prof. O.R. Teshayev

Responsible secretary

prof. F.Kh. Inoyatova

EDITORIAL TEAM

academician Alyavi A.L.

prof. Bilalov E.N.

prof. Gadaev A.G.

prof. Jae Wook Choi (Korea)

academician Karimov Sh.I.

prof. Silina T. (Ukraine)

academician Kurbanov R.D.

prof. Zueva L. (Russia)

prof. Metin Onerc (Turkey)

prof. Mee Yeun (Korea)

prof. Najmutdinova D.K.

assoc. Rakhmatullin A.R. (Russia)

prof. Salomova F.I.

prof. Treskatch S. (Germany)

prof. Shaykhova G.I.

EDITORIAL COUNCIL

DSc. Abdullaeva R.M.

prof. Akilov F.O. (Tashkent)

prof. Allaeva M.D. (Tashkent)

prof. Khamdamov B.Z. (Bukhara)

prof. Iriskulov B.U. (Tashkent)

prof. Karimov M.Sh. (Tashkent)

prof. Mamatkulov B.M. (Tashkent)

prof. Okhunov A.A. (Tashkent)

prof. Parpieva N.N. (Tashkent)

prof. Rakhimbaeva G.S. (Tashkent)

prof. Khamraev A.A. (Tashkent)

prof. Kholmatova B.T. (Tashkent)

prof. Shagizatova B.X. (Tashkent)

*Journal edited and printed in the computer of Tashkent
Medical Academy editorial department*

Editorial board of Tashkent Medical Academy

Head of the department: M.N. Aslonov

Russian language editor: O.A. Kozlova

Uzbek language editor: M.G. Fayzieva

English language editor: A.X. Juraev

Corrector: Z.T. Alyusheva

Organizer: Tashkent Medical Academy

*Publication registered in editorial and information
department of Tashkent city*

Registered certificate 02-00128

*Journal approved and numbered under the order 201/3 from 30 of
December 2013 in Medical Sciences DEPARTMENT OF SUPREME ATTESTATION*

COMMISSION

COMPLETED MANUSCRIPTS PLEASE SEND following address:

*2-Farobiy street, 4 floor room 444. Administration building of TMA.
Tashkent. 100109, Toshkent, ul. Farobi, 2, TMA bosh o'quv binosi, 4-qavat,
444-xona.*

Contact number: 71- 214 90 64

e-mail: rio-tma@mail.ru. rio@tma.uz

Format 60x84 1/8. Usl. printer. l. 9.75.

Listening means «Cambria».

Circulation 150.

Negotiable price

Printed in TMA editorial and publisher department risograph

2 Farobiy street, Tashkent, 100109.

СОДЕРЖАНИЕ

СОДЕРЖАНИЕ		
ОБЗОРЫ	REVIEWS	
Асранкулова Д.Б., Хасанова Ш.Б. СОВРЕМЕННЫЕ ВЗГЛЯДЫ НА КЛИНИКУ И ЛЕЧЕНИЕ ГЕСТАЦИОННО ОБУСЛОВЛЕННЫХ ИНСУЛЬТОВ	Asrankulova D.B., Hasanova Sh.B. MODERN VIEWS ON THE CLINIC AND TREATMENT OF GESTATION-BASED INSULTS	9
Беламанова Л.Ж., Ольшевская Н.В., Кусаинова Б.Х. ПАТОЛОГИЯ ШЕЙКИ МАТКИ У БЕРЕМЕННЫХ	Belamanova L.Zh., Olshevskaya N.V., Kusainova B.Kh. PATHOLOGY OF THE CERVIX IN PREGNANT WOMEN	13
Ботирова Х.Н., Юлдашева С.З. ВЗАИМОСВЯЗЬ МИКРОБИОТЫ КИШЕЧНИКА С РАЗВИТИЕМ СИНДРОМА ПОЛИКИСТОЗНЫХ ЯИЧНИКОВ	Botirova Kh.N., Yuldasheva S.Z. THE RELATIONSHIP BETWEEN GUT MICROBIOTA AND THE DEVELOPMENT OF POLYCYSTIC OVARY SYNDROME	17
G'oyibov S.S., Jamolova F.N. TUG'RUQDAN KEYINGI CHANOQ TUBI NOSOZLIGI	Goyibov S.S., Jamolova F.N. PELVIC FLOOR INSUFFICIENCY AFTER CHILDBIRTH	20
Исчанова С.Д., Юсупова М.А. ДИАГНОСТИКА И ОРГАНОСОХРАНЯЮЩАЯ ТАКТИКА ПРИ ОПЕРАТИВНОМ РОДОРАЗРЕШЕНИИ У ЖЕНЩИН С ВРАСТАНИЕМ ПЛАЦЕНТЫ	Ischanova S.D., Yusupova M.A. DIAGNOSIS AND ORGAN-PRESERVING TACTICS DURING SURGICAL DELIVERY IN WOMEN WITH PLACENTA ACCRETA	22
Ikhtiyarova G.A., Kudratova D.Sh., Goikhman Y.B. CURRENT METHODS OF PREIMPLANTATION GENETIC DIAGNOSIS IN THE REPUBLIC OF UZBEKISTAN	Ixtiyorova G.A., Kudratova D.Sh., Goyxman Y.B. O'ZBEKISTON RESPUBLIKASIDA ZAMONAVIY PREIMPLANTATION GENETIK TEKSHIRUVBUSULLARI	26
Ikhtiyarova G.A., Kudratova D.Sh., Goyxman Y.B. ARTIFICIAL INTELLIGENCE IN OVERCOMING REPEATED FAILURES OF ASSISTED REPRODUCTIVE TECHNOLOGIES	Ixtiyorova G.A., Kudratova D.Sh., Goyxman Y.B. YORDAMCHI REPRODUKTIV TEXNOLOGIYALARDAN KEYINGI TAKRORIY MUVAFFAQUYATSIZLIKARNI SUN'IY INTELLEKT YORDAMIDA YENGISH	31
Ихтиярова Г.А., Салимова Т.Б. ПРОГНОЗИРОВАНИЕ ЭНДОТЕЛИАЛЬНОЙ ДИСФУНКЦИИ У БЕРЕМЕННЫХ С ГИПЕРТЕНЗИВНЫМИ РАССТРОЙСТВАМИ	Ixtiyarova G.A., Salimova T.B. PREDICTION OF ENDOTHELIAL DYSFUNCTION IN PREGNANT WOMEN WITH HYPERTENSIVE DISORDERS	36
Ixtiyorova G.A., Tolibova A.E. ENDOMETRIOID TUXUMDON KISTALARI VA BEPUSHTLIK: DAVOLASH, REJALASHTIRISH VA YRTDAGI INDIVIDUAL YONDASHUVLAR	Ikhtiyarova G.A., Tolibova A.E. ENDOMETRIOID OVARIAN CYSTS AND INFERTILITY: TREATMENT, PLANNING, AND INDIVIDUALIZED APPROACHES IN ART	40
Каримова Г.К., Шарипова Н.М. ГЕСТАЦИОН ҚАНДЛИ ДИАБЕТ ВА УНИ КЕЛТИРИБ ЧИҚАРУВЧИ ХАВФ ОМИЛЛАРНИ ЭРТА БАШОРАТЛАШ	Karimova G.K., Sharipova N.M. EARLY PREDICTION OF GESTATIONAL DIABETES AND ITS RISK FACTORS	46
Максимова М.А. НАРУШЕНИЕ МАТОЧНО-ПЛАЦЕНТАРНО-ПЛОДОВОГО КРОВООБРАЩЕНИЯ: СОВРЕМЕННЫЕ ПОДХОДЫ И КЛИНИЧЕСКИЕ ПЕРСПЕКТИВЫ	Maksimova M.A. DISORDERS OF UTEROPLACENTAL AND FETOPLACENTAL CIRCULATION: MODERN APPROACHES AND CLINICAL PERSPECTIVES	50
Maksudova M.M., Najmutdinova D.K. TUXUMDONLAR FAOLIYATINI TIKLASH VA BEPUSHTLIKNI BARTARAF ETISHDA PRP USULINING SAMARADORLIGI	Maksudova M.M., Najmutdinova D.K. EFFICACY OF PRP IN OVARIAN DYSFUNCTION AND FEMALE INFERTILITY TREATMENT	55
Максудова С.М., Юлдашева С.З. ПАТОФИЗИОЛОГИЧЕСКИЕ АСПЕКТЫ РЕЦИДИВИРУЮЩЕЙ НЕУДАЧИ ИМПЛАНТАЦИИ: МУЛЬТИДИСЦИПЛИНАРНЫЙ ОБЗОР СОВРЕМЕННЫХ ДАННЫХ	Maksudova S.M., Yuldasheva S.Z. PATHOPHYSIOLOGICAL ASPECTS OF RECURRENT IMPLANTATION FAILURE: A MULTIDISCIPLINARY REVIEW OF CURRENT EVIDENCE	59
КЛИНИЧЕСКАЯ МЕДИЦИНА	CLINICAL MEDICINE	
Абдужаппарова Н.Э. СВЯЗЬ ФЕТОПЛАЦЕНТАРНОГО НАРУШЕНИЯ С ПОЛИМОРФИЗМОМ ГЕНОВ ПРИ БЕРЕМЕННОСТИ ПОСЛЕ ЭКСТРАКОРПОРАЛЬНОГО ОПЛОДОТВОРЕНИЯ	Abdujapparova N.E. RELATIONSHIP BETWEEN FETOPLACENTAL DISORDER AND GENE POLYMORPHISM DURING PREGNANCY AFTER IN VITRO FERTILIZATION	61
Абдукаримова Н.Т. АНАЛИЗ РОДОВ И ПОСЛЕРОДОВОГО ПЕРИОДА У БЕРЕМЕННЫХ С МИТРАЛЬНЫМ СТЕНОЗОМ: РЕТРОСПЕКТИВНОЕ ИССЛЕДОВАНИЕ	Abdukarimova N.T. ANALYSIS OF DELIVERY AND POSTPARTUM PERIOD IN PREGNANT WOMEN WITH MITRAL STENOSIS: A RETROSPECTIVE STUDY	65

CURRENT METHODS OF PREIMPLANTATION GENETIC DIAGNOSIS IN THE REPUBLIC OF UZBEKISTAN

Ikhtiyarova G.A.¹, Kudratova D.Sh.², Goikhman Y.B.³

СОВРЕМЕННЫЕ МЕТОДЫ ПРЕИМПЛАНТАЦИОННОЙ ГЕНЕТИЧЕСКОЙ ДИАГНОСТИКИ В РЕСПУБЛИКЕ УЗБЕКИСТАН

Ихтиярова Г.А.¹, Кудратова Д.Ш.², Гойхман Я.Б.³

O'ZBEKISTON RESPUBLIKASIDA ZAMONAVIY PREIMPLANTATSION GENETIK TEKSHIRUVBUSULLARI

Ixtiyorova G.A.¹, Kudratova D.Sh.², Goyxman Y.B.³

¹Bukhara State Medical Institute,

²Tashkent State Dental Institute, ³Israeli Medical Center

Более чем за 20 лет, в течение которых существует преимплантационная генетическая диагностика, возможности вспомогательных репродуктивных технологий и потенциал молекулярно-генетической диагностики одиночных клеток значительно расширились. К настоящему времени преимплантационная диагностика прошла путь от экспериментальной процедуры до валидной и наиболее ранней формы пренатальной диагностики, расширив при этом спектр показаний. Представлено современное состояние преимплантационной генетической диагностики, описаны принципы и показания к ее проведению.

Ключевые слова: преимплантационная генетическая диагностика; пренатальная диагностика.

Преимплантационная генетическая диагностика 20 yildan ortiq vaqtdan beri mavjud bo'lib, shu vaqt ichida yordamchi reproduktiv texnologiyalarning imkoniyatlari va bitta hujayraning molekulyar genetik diagnostikasi imkoniyatlari sezilarli darajada kengaydi. Bugungi kunga qadar преимплантационная диагностика eksperimental usuldan prenatal diagnostikaning haqiqiy va eng erta shakliga aylandi, shu bilan birga ko'rsatkichlar doirasini kengaytirdi. Sharhda преимплантационная генетическая диагностика hozirgi holati ko'rsatilgan, uni amalga oshirish tamoyillari va ko'rsatmalari tavsiflangan.

Kalit so'zlar: преимплантационная генетическая диагностика; пренатальная диагностика.

Обзоры

Prevention of the birth of children with hereditary diseases is one of the urgent tasks of modern medicine. Currently, to accomplish this task, methods of prenatal diagnosis (PD) are used, aimed at identifying pathological conditions in the fetus during progressive pregnancy, and preimplantation genetic diagnosis (PGD / PGD - Preimplantation Genetic Diagnosis), which allows to study the genome of the embryo before its transfer to the uterine cavity [12]. PD of monogenic and chromosomal diseases is performed mainly using invasive methods for obtaining fetal material (chorionic or placental villus biopsy, amniocentesis, cordocentesis) and subsequent molecular genetic or cytogenetic studies. If PD reveals a genetic disorder in the fetus, then the pregnancy can be interrupted artificially. In some cases, spouses who are aware of the identified pathology in the fetus decide to continue the pregnancy [8]. The adoption of such a decision must be necessarily consulted by a specialist, a married couple must understand the responsibility that falls on them and be aware of the need for large material and moral costs associated with the care and social adaptation of such children. It is important that spouses know that the life expectancy of people with a genetic pathology is much less than in the normal population. PGD, unlike PD, is performed before implantation of the embryo into the uterine wall. Carrying out genetic diagnostics before implantation is possible only in case of in vitro fertilization, that is, when using Assisted Reproductive Technologies (ART). The PGD procedure involves biopsy of one or more cells from an oocyte

(polar bodies) or embryo (blastomeres, trophectoderm cells) and their subsequent genetic testing for gene or chromosome mutations [14,15]. In the absence of a test pathology, the embryo can be transferred into the uterine cavity or cryopreserved until transfer in the next IVF cycle. Now the most promising is the diagnosis of embryos at the blastocyst stage, with the study of 3-8 cells of the trophectoderm. Currently, for the genetic study of embryonic cells, fluorescent in situ hybridization (FISH - Fluorescence in situ hybridization) or polymerase chain reaction (PCR / PCR - Polymerase chain reaction) is usually used [1,5]. Less commonly used is a more expensive method - comparative genomic hybridization using microarrays (array comparative genomic hybridization - a CGH). Modern possibilities of preimplantation genetic diagnosis are developing rapidly, and, apparently, will expand the possibilities of IVF with PGD in the near future. Indications for PGD are divided into several groups (Table).

The first group is a high genetic risk of transmission of hereditary pathology to offspring. Such diagnostics are carried out for carriers of gene and chromosomal abnormalities [3]. These can be monogenic diseases (autosomal recessive, autosomal dominant, linked to the X or Y chromosome), as well as chromosomal abnormalities (numerical and structural aberrations of chromosomes). It is important for a geneticist whose task is to help a family have a healthy child, it is important to remember that among patients in need of such a diagnosis, there may be patients with gonadal mosaicism. This

means that a genetic analysis of a patient's blood sample will not show the presence of a mutation. It is possible to assume gonadal mosaicism in a patient according to the anamnestic analysis of his family - a study of sick children in the family, abortion material from previous pregnancies and embryos obtained in IVF cycles.

The second group is the presence of a high risk of formation of aneuploid gametes with a normal somatic karyotype. In this case, the number of certain chromosomes in pre-implantation embryos is analyzed. This diagnosis is called Preimplantation Genetic Screening (PGS - Preimplantation Genetic Screening).

Table

Indication	Patient group	Diagnostic methods
High genetic risk of transmission of hereditary pathology to offspring	Carriers of gene mutations that cause monogenic diseases: autosomal recessive, autosomal dominant, linked to the X or Y chromosome)	PCR
	Carriers of chromosomal abnormalities: numerical and structural aberrations of chromosomes	FISH, PCR, a-CGH, SN-Parrays
High risk of formation of aneuploid gametes with normal somatic karyotype	Women of older reproductive age — 35 (38) years and older; • couples with a history of more than three spontaneous abortions in early pregnancy (recurrent miscarriage); • men with severe disorders of spermatogenesis: oligoasthenoteratozoospermia, severe oligozoospermia, azoospermia; • couples with repeated IVF failures (more than three failures of unknown cause)	FISH, PCR, a-CGH, SN-Parrays
A high risk of developing a severe disease in the offspring with late manifestation, incl. oncological disease	Carriers of gene mutations that significantly increase the risk of developing cancer and diseases with late PCR manifestation	PCR
The presence in the family of a child with a hematological disease who needs a transplant of donor hematopoietic stem cells to continue life	Carriers of hereditary hematological diseases; • families with a child with a sporadic hematological disease	PCR
High risk of severe mitochondrial disease in offspring	Female carrier of a specific mtDNA mutation	PCR
Family planning	Married couples who, for objective reasons, plan to have a child of a certain gender	FISH, PCR

Обзор

Currently, FISH can routinely determine the number of 9-12 chromosomes. The chromosomes to be tested are selected based on their significance for prenatal and postnatal development. It is advisable to test the number of chromosomes - 8, 9, 13, 14, 15, 16, 17, 18, 21, 22, X, Y [2,6]. It has been shown that determining the number of five chromosomes makes it possible to identify 40%, and twelve chromosomes about 90% of all chromosomal abnormalities in embryos that have reached the blastocyst

stage [13]. The a CGH method allows you to determine the number of all human chromosomes and investigate the imbalance in individual chromosome segments. In the last three years, European countries and the United States have begun to actively use the a CGH method for PGD [7,9]. The use of SNP-arrays, microarrays based on single nucleotide substitutions (SNP, single nucleotide polymorphism), makes it possible to simultaneously label more than a million chromosomal loci [4].




Figure. Results of screening analyzes of the incidence of CM conclusion, %.

The prospects for a CGH for PGS are obvious, but so far, along with a high cost, the method has disadvantages: the inability to determine the ploidy of a cell and the inability to distinguish a karyotype with a balanced structural rearrangement of chromosomes from a normal one. The following groups of patients have an increased risk of formation of aneuploid gametes: 1. Women of older reproductive age - 35 years and older. 2. Couples with a history of more than three spontaneous abortions in the early stages (recurrent miscarriage). 3. Men with severe disorders of spermatogenesis - oligoasthenoteratozoospermia, severe oligozoospermia, azoospermia. 4. Married couples with repeated IVF failures - more than three unsuccessful attempts (it should be remembered that this group is especially heterogeneous, other factors of IVF failure must be excluded). It is important to remember that in all patients referred for PGS, a normal karyotype must be confirmed, and for patients in groups 2, 3, and 4, non-genetic causes of the pathology must be excluded. PGS accounts for about 60% of all PGDs performed in the world, however, the importance of pre-implantation screening for aneuploidies has been debated among IVF specialists for five years. PGS began to be carried out in the early 1990s [10,11] in order to improve the results of IVF by transferring embryos without aneuploidy into the uterine cavity, the most significant for pre- and postnatal development. Since numerous studies have shown that 50–60% of spontaneous abortions of early pregnancies are associated with chromosomal pathology in the fetus [11], it was clear that when embryos are transferred after PGS, the frequency of spontaneous pregnancy losses will be less and, consequently, the IVF result better. In addition, when transferring embryos without frequent chromosomal abnormalities, an increase in the frequency of implantation was expected. By 2010, numerous results were obtained indicating that PGS increases the frequency of implantation, reduces spontaneous early pregnancy losses, and increases the frequency of birth of healthy children (“taking home baby”) after IVF in families at risk [11]. Most of the published data on PGS come from non-randomized retrospective studies with a high level of significance (2nd or 3rd level of significance), however, randomized trials (RI) in this area are almost non-existent. In 2023, a Dutch group of specialists published the results of a large RI of the effectiveness of OPO [11]. The results indicated a negative effect of PGS on the outcomes of IVF cycles, which was the beginning of an ongoing discussion among various specialists in reproductive medicine. The study of the Dutch group has many significant methodological shortcomings, which are detailed in a number of authoritative publications [10,11]. These shortcomings make it untenable to draw conclusions about the significance of PGD in IVF, but it cannot be said that this study was very useful in revising the indications for PGS, methodological progress in PGD, developing a quality control system in PGD, and even stimulating research in the field of human embryology. To date, only 12 RIs on PGS have been published [10], and a meta-analysis of these studies has been carried out [10]. All published RIs have significant shortcomings

(controversial methodological approaches, insufficient number of patients, organization - “design” of the study, etc.), which makes it impossible even with the help of a meta-analysis to draw an unambiguous conclusion about the effect of PGS on the IVF outcome. It is clear that an incorrectly organized PGS will not improve the outcome of IVF, and further RI in the form in which it was carried out does not make sense and is unethical in relation to patients. All experts agree that a high level of mosaicism in preimplantation human embryos reduces the positive effect of preimplantation screening for aneuploidies – new methodological approaches are needed, as well as additional studies of the significance of mosaicism for different stages of human embryonic and prenatal development. Despite the controversy around PGS, it is clear that, if properly organized, the method significantly expands the possibilities of IVF and can be called the earliest PD method that prevents the implantation of embryos with complete and partial aneuploidies and, therefore, prevents spontaneous abortions and the birth of children with chromosomal pathology. The third group – carriage of gene mutations that can cause diseases with late manifestation, manifested in adulthood or old age, including mutations predisposing to the development of oncological diseases. Such carriage was not a standard indication for PD, however, in some cases, for example, with a mutation in the RB1 gene predisposing to the occurrence of retinoblastoma, the probability of developing the disease in offspring in the case of transmission of the mutant allele is about 90%. Doing PD with subsequent possible termination of pregnancy for this group of patients is not considered justified. PGD, in contrast, may be chosen by spouses to prevent transmission of the disease to the next generation. Currently, PGD regimens have been developed for oncological diseases such as Li-Fraumeni syndrome (p53), retinoblastoma (RB1), familial polyposis (APC), neurofibromatosis I (NF1) and II (NF2), familial breast and ovarian cancer (BRCA1, BRCA2), ataxia-telangiectasia (ATM), etc. The results of successful PGD in early-onset familial Alzheimer’s disease (APP gene mutation) have been published. The fourth group is the presence in the family of a child with a hematological disease who needs a transplantation of donor hematopoietic stem cells to continue life. For the first time, such PGD was performed 11 years ago to save a girl with Fanconi anemia. After that, for several years, European experts discussed the ethics of such PGD and came to the conclusion that this diagnosis has a right to exist. Currently, the treatment of sick siblings with bone marrow transplantation of healthy HLA-identical siblings born as a result of IVF with PGD is not a rare event. It is clear that PD is impossible in this case, the theoretical probability ISSN 1684-0461 sick child is low. To date, there are the following indications for PGD with HLA-typing: hereditary diseases complicated by bone marrow insufficiency, hemoblastoses, immunodeficiencies, and metabolic diseases such as X-linked adrenoleukodystrophy. In addition, preimplantation HLA typing is used to treat sporadic hematological diseases; for the first time, the method was used to treat a sibling patient with hypoplastic Blackfan–

Diamond anemia [38]. The fifth group is the carriage of genetic diseases caused by mutations in mitochondrial DNA (mtDNA). Since the zygote receives all the mitochondria from the egg, these diseases are maternally inherited. Mitochondrial diseases caused by nuclear DNA mutations are transmitted according to Mendelian laws, therefore, the PGD regimen should be the same as for monogenic diseases. The inheritance of mitochondrial diseases caused by mtDNA mutations is complicated by heteroplasmy (genetic heterogeneity of the mitochondrial population), different levels of heteroplasmy in different oocytes, random distribution of mtDNA molecules between blastocyst cells, and the fact that the proportion of mutant mtDNA molecules can change differently in tissues during development and life of the organism. The manifestation of diseases caused by mtDNA mutations is very variable, the symptoms of some diseases vary both between families and within the same family. Even though disease severity depends on a particular mtDNA mutation and the number of mutated molecules, there are numerous exceptions. The difficulty of predicting the course of many mitochondrial diseases, and the impossibility of selecting embryos completely free of mutant mtDNA during PGD, makes it very difficult to perform this kind of PGD. Currently, it is recommended to develop PGD for mtDNA mutations within the research protocol and to inform potential parents that the first cycle of PGD can only be performed to collect information regarding the reliability of the method. To date, few data on clinical cycles of PGD in mtDNA mutations have been published. The sixth group is the determination of the sex of embryos for the purpose of family planning. In European countries and the United States, such a diagnosis is called "social sexing". According to the PGD consortium ESHRE (European Society of Human Reproduction and Embryology), there is a decrease in such diagnoses worldwide. According to the latest published data of the consortium, the share of such PGD in 2007 was 1.6%, and in the previous nine years it was 2.7%. Carrying out PGD for the purpose of family planning cannot be considered unambiguously justified. However, if we compare this method with PD carried out for the purpose of family planning, where in most cases, when a fetus of an "unwanted" sex is identified, an artificial termination of pregnancy is assumed, PGD seems to be more humane. Since November 2011, sex selection of pre-implantation embryos for transfer without medical indications has been prohibited by law in the Russian Federation. Despite the fact that pre-implantation diagnostics has been carried out since 1989, PGD methods and coordination of processes during diagnostics have not yet been standardized. In recent years, worldwide attention has been paid to standardization, internal and external quality control of PGD procedures. This is very important to reduce the error of the method, which, if the relevant requirements are not met, can be significant. Standardization of PGD procedures improves the quality of services, creates optimal conditions for the work of specialists, and increases the security of patients. This is especially true when the diagnosis is carried out according to the "transport scheme" - that is, dif-

ferent stages of IVF with PGD are performed in different medical institutions located in different cities or even countries. The "transport scheme" is widely used in the Americas and Europe. This is due to the fact that it is not yet economically viable to maintain expensive equipment for genetic research and a staff of highly qualified employees in small and medium-sized ART clinics. Clinical and laboratory departments are connected using special couriers and standard means of communication (Internet, telephone). The outcome of IVF cycles with PGD largely depends on the clarity of coordination between departments. Currently, two large international medical organizations: the PGD Consortium (ESHRE) and the International PGD Community (PGDIS) continue to develop standards for PGD procedures [10]. American specialists — American Society for Assisted Reproductive Technology (SART) with American ISSN 1684-0461 Reproductive Medicine (ASRM - American Society for Reproductive Medicine) also work in this area. Recently, projects on external quality control of PGD procedures have been launched in Europe: by the FISH method and by the PCR method. International PGD communities, individual authorities in the field of PGD and regulatory medical authorities in different countries recommend that all PGD laboratories be accredited in accordance with internationally recognized quality standards or conduct activities that will facilitate such accreditation in the future. To date, two programs of the International Organization for Standardization - ISO (ISO - International Organization for Standardization) have been tested in Europe. Here we present a possible scheme for carrying out PGD procedures, taking into account the interaction between different departments of the ART clinic and the genetic laboratory, taking into account PGD according to the "transport scheme". This flowchart is designed to standardize the processes involved in PGD, to easily identify the different stages and checkpoints of a procedure, and to establish links between them. The scheme is necessary for quick quality control of the work of specialists (doctors of reproductive medicine, geneticists, genetics laboratory assistants, biologists, paramedical personnel, etc.) and convenient coordination of their actions. PGD has been developing for more than 20 years, during this time there has been significant progress in IVF techniques, new methods and equipment have appeared that allow expanding the range of ART capabilities. The changes that have taken place during this time in molecular diagnostics are even more impressive; at present, PGD has in its arsenal accurate and universal methods that make it possible to study many genetic markers of a single cell in less than a day. As a result, PGD has evolved from an experimental procedure to a valid and earliest form of PD, while expanding the range of indications. Further development of molecular diagnostic methods, their standardization for PGD, combined with improved organization and coordination of processes in IVF cycles with PGD, promises good prospects.

The list of references is available at the editorial office

CURRENT METHODS OF PREIMPLANTATION GENETIC DIAGNOSIS IN THE REPUBLIC OF UZBEKISTAN

Ikhtiyarova G.A., Kudratova D.Sh., Goikhman Y.B.

Preimplantation genetic diagnosis has existed for more than 20 years, during which time the range of possibilities of assisted reproductive technologies and the potential of molecular genetic diagnosis of single cells have

significantly expanded. To date, preimplantation diagnosis has evolved from an experimental procedure to a valid and earliest form of prenatal diagnosis, while expanding the range of indications. The review presents the current state of preimplantation genetic diagnosis, describes the principles and indications for its implementation.

Key words: preimplantation genetic diagnosis; prenatal diagnosis.

About the Authors

Ikhtiyarova Gulchekhra Akmalevna, Head of the Department of Obstetrics and Gynecology No. 1 BukhMI. Tel: +99890 7181917, e-mail: ixtiyarova7272@mail.ru, <https://orcid.org/0000-0002-2398-3711>

Kudratova Dilnoza Sharifovna, PhD, Assoc. Prof. TGSI. Tel: 998905106555, e-mail: dilnoza.kudratova@mail, <https://orcid.org/0009-0007-9961-5695>

Goykhman Yaron Borisovich, founder of the IMC clinic. Tel: +998900080034, e-mail: dr.yaron@ivf.uz, <https://orcid.org/0009-0006-79966351>

